Vertex Pharmaceuticals Inc (VRTX)

87.24
2.20 2.60
NASDAQ : Health Care
Prev Close 85.00
Open 85.25
Day Low/High 83.50 / 88.91
52 Wk Low/High 75.90 / 143.45
Volume 2.53M
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 247.78M
Market Cap 22.01B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Vertex Pharmaceuticals Takes Over #81 Spot From Starbucks

Vertex Pharmaceuticals Takes Over #81 Spot From Starbucks

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Vertex Pharmaceuticals, Inc. has taken over the #81 spot from Starbucks Corp.

Vertex Provides Update On Ongoing Phase 3 Program For VX-661 In Combination With Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Provides Update On Ongoing Phase 3 Program For VX-661 In Combination With Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies...

Listen Up and Pay Attention to the Utes

This is where a lot of money has been parked in the last year.

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

The company also could look to acquire a smaller biotech company, though likely not Medivation.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMOT, ANGI, CBT, ELY, FTAI, GNBC, LOGM, NCR, SIX, SKUL, SLAB, SNY, SONS, TRK, TRN, UFS, VRTX, WES, ZNGA Downgrades: AF, BA, TER, WEX Initiations: FSV Read on to get TheStreet Quant Ratings' detailed report:

Vertex Reports Second Quarter 2016 Financial Results

Vertex Reports Second Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2016 and reviewed recent progress with its approved and investigational cystic fibrosis...

A 'Semi-Charmed' Kind of NXPI Call Spread

A 'Semi-Charmed' Kind of NXPI Call Spread

It might be best to make this a late-afternoon purchase.

Vertex To Announce Second Quarter 2016 Financial Results On July 27

Vertex To Announce Second Quarter 2016 Financial Results On July 27

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close.

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.

Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates

Wall Street Closes Higher as Fed Doves Make Case for Waiting on Rates

A dovish Federal Reserve in June pushes equities, crude to close around session highs.

Stocks Add to Gains as Fed Stresses Prudence in Policy-Making

Stocks Add to Gains as Fed Stresses Prudence in Policy-Making

Stocks add to gains by late afternoon Wednesday after the Federal Reserve's June meeting minutes confirm members' prudent approach to monetary policy.

Vertex And Moderna Establish Exclusive Collaboration To Discover And Develop MRNA Therapeutics™ For Cystic Fibrosis

Vertex And Moderna Establish Exclusive Collaboration To Discover And Develop MRNA Therapeutics™ For Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Moderna Therapeutics today announced that the two companies have entered into an exclusive research collaboration and licensing agreement aimed at the discovery...

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

The New #41 Most Shorted Nasdaq 100 Component: Vertex Pharmaceuticals

The New #41 Most Shorted Nasdaq 100 Component: Vertex Pharmaceuticals

The most recent short interest data has been released for the 06/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Vertex Announces Presentations Of Data For KALYDECO® (ivacaftor) And ORKAMBI® (lumacaftor/ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference

Vertex Announces Presentations Of Data For KALYDECO® (ivacaftor) And ORKAMBI® (lumacaftor/ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced presentations of KALYDECO ® (ivacaftor) and ORKAMBI ® (lumacaftor/ivacaftor) data at the 39 th European Cystic Fibrosis Society (ECFS)...

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Vertex To Present At The Goldman Sachs Healthcare Conference On June 7

Vertex To Present At The Goldman Sachs Healthcare Conference On June 7

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference in Rancho Palos Verde, CA on Tuesday, June 7 th at 1:40 p.

Vertex Pharmaceuticals Becomes #243 Most Shorted S&P 500 Component, Replacing Coach

Vertex Pharmaceuticals Becomes #243 Most Shorted S&P 500 Component, Replacing Coach

The most recent short interest data has been released for the 05/13/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Cramer: How Did the Stock Market Get So Unwieldy?

The answer is that new data came out.

Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16

Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16

Vertex Pharmaceuticals tried to soothe fears about the commercial ramp of its cystic fibrosis franchise by providing Orkambi sales guidance for the first time since the drug launched last summer.

Post-Market Activity Shows Vertex Pharmaceuticals (VRTX) Down

Post-Market Activity Shows Vertex Pharmaceuticals (VRTX) Down

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a post-market laggard candidate

Vertex Reports First Quarter 2016 Financial Results

Vertex Reports First Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2016 and provided an update on its approved CF medicines and other investigational...

Charts Say Vertex Could Recover

The rate of decline slowed into the base, just what chartists like to see. 

3 Compelling Reasons to Buy This Undervalued Biotechnology Stock

3 Compelling Reasons to Buy This Undervalued Biotechnology Stock

For investors who want to profit from this resurgent sector, Vertex Pharmaceuticals is set for stellar growth, but it is also ridiculously cheap.

5 Toxic Stocks You Should Sell Now

5 Toxic Stocks You Should Sell Now

It's time to unload these toxic stocks from your portfolio.